Consulting Services
Launch Planning
Real-World Evidence Strategy
Study Endpoint Selection
- Burden of illness studies
- Unmet need assessment
- Value proposition
- Evidence generation
- Publication planning
- Coding, coverage, & payment
- ICER and HTA planning
Study Endpoint Selection
Real-World Evidence Strategy
Study Endpoint Selection
- Patient-reported Outcomes
- Clinician-reported Outcomes
- Health economic endpoints
Real-World Evidence Strategy
Real-World Evidence Strategy
Real-World Evidence Strategy
- RWE strategy development
- Study design
- Endpoint selection
- Publication planning
Leadership
Carole Dembek
Carole Dembek is Founder and Principal of HealthEcon Strategies, LLC. Carole brings over 25 years of experience in the biopharma and medical device industries with expertise in health economics, outcomes research, and global market access.
Carole is proficient at developing and executing global strategies to optimize product value and patient access. Carole's expertise includes health economics and outcomes research (HEOR), global and US launch planning, evidence generation, publication strategy, and value proposition development. Carole has experience in numerous therapeutic areas including psychiatry, neurology, respiratory, endoscopy, and interventional cardiology. She has presented her research at medical conferences and published over 30 papers in peer-reviewed medical journals.
Carole received her Bachelor of Science Degree in Medical Technology from the University of Michigan and her Master of Science Degree in Health Policy and Management from the Harvard University School of Public Health. After living in Massachusetts for over 30 years, Carole and her husband now live in Maine where they enjoy kayaking, hiking, and boating.
Contact information:
Selected Publications
Economic Burden
- Dembek C, Mackie D, Modi K, Zhu Y, Niu X, Grinnell T. The economic and humanistic burden of bipolar disorder in adults in the United States. Annals of General Psychiatry. (2023) 22:13.
- Kadakia A, Catillon M, Fan Q, Williams GR, Marden JR, Anderson A, Kirson N, Dembek C. The Economic Burden of Schizophrenia in the United States. J Clin Psychiatry. 2022 Oct10;83(6).
Observational Real-World Studies
- Stephenson JJ, Dembek C, Caldwell-Tarr A, Conto RM, Paullin M, Kerwin EM. Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow CS. Int J Chron Obstruct Pulmon Dis. 2020 Jul 13; 15:1713-1727.
- Kadakia A, Dembek C, Liu, Dieyi C, Williams GR. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study. J Med Econ. 2021 Jan-Dec;24(1):1212-1220.
Network Meta-Analysis
- Kadakia A, Dembek C, Heller V., et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry. 2021 May 11;21(1):249.
Cost-Effectiveness
- Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A. Cost-effectiveness of Twice Daily Indacaterol/glycopyrrolate Inhalation Powder for the Treatment of Moderate to Severe COPD in the US. Int J of Chron Obstruc Pulm Dis. 2018:13;3867-3877.
- Dembek C, White LA, Quach J, et al. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain. Eur J of Health Econ. 2014 May;15(4):353-362.
Health-related Quality of Life
- Dembek C, Fan Q, Niu X, et al. Impact of lurasidone on health-related quality of life in adults with bipolar disorder: a post-hoc analysis. Curr Med Res Opin. 2022 Sep;38(9):1613-1619.
- Mahler D, Kerwin E, Murray L, Dembek C. The Impact of Twice-Daily Indacaterol/Glycopyrrolate on the Components of Health-Related Quality of Life and Dyspnea in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease. 2019 Oct 23;6(4)308-320.
Health Resource Use
- Huang H, Schmerold L, Dembek C, et al. Healthcare Resource Utilization, Costs, and Treatment Patterns in Patients with Bipolar Disorder Treated with Lurasidone or Cariprazine. J Med Econ, 2021 Jan-Dec; 24(1)352-362.
Contact Us
HealthEcon Strategies, LLC
411 Memorial Drive, Winthrop, Maine 04364, United States
